Techniclone Corporation was issued U.S. Patent No. 6,036,955 on March 14, 2000 entitled “Kits and Methods for the Specific Coagulation of Vasculature” by the U.S. Patent and Trademark Office.
This patent covers particular methods of inducing molecules on tumour blood vessels for subsequent targeting and destruction and is a valuable addition to Techniclone’s existing broad patent portfolio on its Vascular Targeting Agent (VTA) technology.
Dr. John Bonfiglio, Interim President, stated, “We are very happy to have received another patent for Techiclone’s proprietary VTA technology platform. This patent continues to strengthen our already strong patent position in this field.
Clearly the value of Techniclone’s patent position is evidencing itself through negotiations in progress and recently signed letters of intent with Oxigene, Inc. and SuperGen, Inc.”
The VTA technology is Techniclone’s proprietary therapeutic platform designed to specifically target tumour vasculature and subsequently destroy the tumour with various attached therapeutic agents.
Although VEGF alone is being examined by many companies as a target for anti-angiogenisis agents, Techniclone holds the patents for attaching most therapeutic agents to VEGF for the purpose of targeting them to the tumour vasculature.
Dr. Philip Thorpe, Professor of Pharmacology at the University of Texas, Southwestern Medical Centre at Dallas, and the lead inventor of the VTA technology has shown proof of principle with this technology in several animal models, the results of which studies have been published in peer reviewed scientific journals, including Science in 1997.
TECHNICLONE Corporation is a biopharmaceutical company focused on the development, commercialisation and licensing of unique technologies for the treatment of cancer, primarily based on its collateral targeting technologies.
These technologies therapeutically target cell structures and cell types, rather than surface cancer cells, as a means to attack solid tumours, without causing damage to surrounding healthy tissue.
The Company has three collateral technologies: Cotara (T, Vasopermeation Enhancement Agents (VEA), and Vascular Targeting Agents (VTA). The Company also has a direct tumour targeting agent called Oncolym for the treatment of advanced non-Hodgkin’s B-cell Lymphoma.
Oncolym has been licensed to Schering AG, Germany, which is now responsible for all existing and future Oncolym clinical trial programs as well as marketing.